Trials / Completed
CompletedNCT04222725
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
A Multicenter, Double-Masked, Randomized, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety of TRS01 Eye Drops in Participants With Post-surgical Inflammation
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Tarsier Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRS01 eye drops | Dosed 4 times a day (QID) |
| DRUG | TRS01 eye drops | Dosed QID |
| DRUG | TRS01 eye drops | Dosed QID |
| DRUG | Placebo eye drops | Dosed QID |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-07-17
- Completion
- 2020-07-17
- First posted
- 2020-01-10
- Last updated
- 2021-10-14
- Results posted
- 2021-10-14
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04222725. Inclusion in this directory is not an endorsement.